The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity ; volume:47 ; number:1 ; day:13 ; month:11 ; year:2023 ; pages:13-29 ; date:2.2024
Inflammation ; 47, Heft 1 (13.11.2023), 13-29, 2.2024
- Urheber
-
Reali, Eva
Caliceti, Cristiana
Lorenzini, Antonello
Rizzo, Paola
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s10753-023-01915-1
- URN
-
urn:nbn:de:101:1-2024040213351989054637
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Reali, Eva
- Caliceti, Cristiana
- Lorenzini, Antonello
- Rizzo, Paola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Current Disease-Modifying Therapies in Multiple Sclerosis
Serum fatty acid profile in psoriasis and its comorbidity
Signaling pathways and targeted therapies for psoriasis
Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD
Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema
Correction: Signaling pathways and targeted therapies for psoriasis
Renin Angiotensin system-modifying therapies are associated with improved pulmonary health
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Exacerbation
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Serum fatty acid profile in psoriasis and its comorbidity
Signaling pathways and targeted therapies for psoriasis
Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD
Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema
Correction: Signaling pathways and targeted therapies for psoriasis
Renin Angiotensin system-modifying therapies are associated with improved pulmonary health
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Exacerbation
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Type-1 spinal muscular atrophy cohort before and after disease-modifying therapies
Current Disease-Modifying Therapies in Multiple Sclerosis
Serum fatty acid profile in psoriasis and its comorbidity
Signaling pathways and targeted therapies for psoriasis
Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD
Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema
Correction: Signaling pathways and targeted therapies for psoriasis
Renin Angiotensin system-modifying therapies are associated with improved pulmonary health
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Exacerbation
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies